SOT109 is an ADC candidate targeting cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers (CRC) and abundantly expressed in other GI cancers, including gastric, pancreatic, and esophageal cancers. SOT109 utilizes Synaffix’s proprietary GlycoConnect™ HydraSpace™ clinical-stage conjugation platform, incorporating the SYNtecan E™ proprietary linker-payload system that contains an exatecan payload (DAR=4). Synaffix’s conjugation technology, which replaces the existing antibody glycan with a therapeutic payload, combined with optimized linker, enables wide therapeutic efficacy and tolerability (learn more here).